What the market corrected
UK digital health hiring reset hard between 2023 and 2025. What did not survive was headcount distant from either clinical delivery or revenue: large undifferentiated product teams, growth roles with no channel specificity, and clinical advisory posts with no operational accountability.
What did survive, and what is hiring now, sits close to the pathway. Clinicians who can run a service. Product people who understand regulated release cycles. Commercial leaders who have closed with PMI, employers or the NHS specifically. AI people who can hold a safety case.
The regulated part is the differentiator
A product manager from consumer software can learn a health domain. What takes longer is internalising that a release can be a clinical risk event, that a UX change may need a safety case update, and that a feature flag rollout has a duty of candour dimension if it goes wrong.
That is why UK digital health employers pay a premium for regulated-domain experience, and why candidates crossing in from adjacent regulated sectors, fintech, aviation, pharma, transfer better than candidates crossing in from consumer tech.
Where clinical and commercial meet
The hardest roles to fill in UK digital health are the hybrid ones. A Medical Director who can hold a P&L conversation. A commercial director who can survive a clinical veto without treating it as an obstacle. A clinical operations lead who can forecast capacity and defend it to a board.
These profiles are rare because the career paths that produce them are accidental. Scale Health spends most of its search time on exactly this intersection, and it is why we assess against clinical and commercial competence separately rather than as one score.
AI in UK health is a governance job first
Almost every AI role we handle in regulated UK health is constrained by the safety case, the evaluation standard and the deployment defence, not by modelling capability. Candidates who lead with model architecture and cannot discuss clinical evaluation do not get through second stage.
The strongest profile currently is someone with genuine ML literacy who is energised rather than frustrated by clinical risk management. That person is scarce, and UK employers are paying £110,000 to £150,000 for them at lead level.
Equity, stage and what to check
Digital health equity is worth interrogating. Ask for the strike price, the last round's preference structure and the runway. A large option grant in a company with three times liquidation preference and nine months of cash is a smaller number than it looks.
Stage matters more than sector here. Series A digital health is a fundamentally different job from a scaled provider with an NHS contract, and candidates who move between them without adjusting expectations tend to be the ones who leave inside a year.
How Scale Health handles digital health mandates
Clinical, product, commercial, governance and AI mandates across the same provider set
Stage, runway and funding position stated openly on every brief
Channel experience verified before commercial introductions, PMI, employer, NHS and D2C
Board and NED introductions where the organisation needs clinical accountability at that level